BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Institute of Oncology - ECPv6.17.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.bricbordeaux.com/en/
X-WR-CALDESC:Events for Bordeaux Institute of Oncology
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241202T140000
DTEND;TZID=Europe/Paris:20241202T170000
DTSTAMP:20241128T154500Z
CREATED:20241128T154500Z
LAST-MODIFIED:20241128T154500Z
UID:48261-1733148000-1733158800@www.bricbordeaux.com
SUMMARY:Thesis defense Guillaume Herrault\, team 6
DESCRIPTION:Cancer Biology thesis defense : Guillaume Herrault\, Team 06 – MIRCADE\, Methods and Innovations for the Research in Pediatric Cancers. \nMonday\, December 2. Closed session \n“Nouvelles stratégies thérapeutiques dans le traitement du gliome infiltrant du tronc cérébral.” \nJury members:\nM. Nicolas LARMONIER\, Professeur des universités\, Université de Bordeaux\, Examinateur\nM. Eddy PASQUIER\, Directeur de recherche\, Aix Marseille Université\, Rapporteur\nMme Isabelle PELLIER\, Professeure des universités – praticienne hospitalière\, Université d’Angers\, Rapporteur\nM. Christophe GROSSET\, Directeur de recherche\, Université de Bordeaux\, Directeur de thèse
URL:https://www.bricbordeaux.com/en/event/thesis-defense-guillaume-herrault-team-6/
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/11/soutenance-de-these-guillaume-herrault.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241209
DTEND;VALUE=DATE:20241211
DTSTAMP:20241118T164717Z
CREATED:20240415T151530Z
LAST-MODIFIED:20241118T164717Z
UID:46419-1733702400-1733875199@www.bricbordeaux.com
SUMMARY:"Neuro-oncology meets Neuroscience" Symposium
DESCRIPTION:\n\n          NEURO-ONCOLOGY MEETS NEUROSCIENCE\n         \n\n  \n\n\n          The Bordeaux Cancer Neuroscience (BCN) Initiative\n         \n\nSymposium organized by Andreas Bikfalvi\, Ahmad Sharanek\, Thomas Mathivet\, Lucie Brisson\, Antonio Pagano Zottola équipe 1 de notre unité BRIC\, Valentin Nägerl (Institut interdisciplinaire de neurosciences\, IINS) and Thomas Daubon (Institut de Biochimie et Génétique Cellulaires\, IBGC) \n\nGlioblastoma (GB) is the most aggressive brain tumor characterized by high proliferation rate\, core necrosis\, microvascular proliferation and tumor infiltration. GB treatment consists in tumor resection by surgery and radiotherapy plus concomitant chemotherapy with temozolomide (Stupp et al\, 2005). However\, GB still remains incurable with a low median survival rate of approx. 15 months.    This is due to resistance to treatment mainly caused by the presence of tumor cells that escape tumor resection by invading the normal brain parenchyma. Recent developments in immunotherapy did not succeed in overcoming this challenge. Unfortunately\, the mechanisms underlying GB development are still not fully understood and current model systems addressing these questions are not adequate\, impeding progress for the field. It has been shown that the tumor microenvironment (TME) in GB partially controls tumor growth and invasion\, and constitutes a therapeutic target (Bikfalvi et al\, 2022). A body of recent studies points to an important role of the normal neuronal brain environment in GB progression.     \n\n\n          This meeting brings people together from both\, the neuro-oncology and neuroscience communities to highlight these new developments occurring at the interface between neuro-oncology and the neurosciences.\n         \n\n          \n            The conference is open to the general public with a half-day specifically dedicated to the Patients/Medical Staff/Researchers triptych (in French)\, organized by Sophie North (BRIC-BoRdeaux Institute of onCology).\n          \n         \n\n\n           \n           \nAll information and registrations : https://nomn2024.sciencesconf.org/ \nRegistration deadline: December 1st 2024 \nAbstract submission for poster presentation deadline : December 1st 2024 \nAbstract submission for flash poster presentation deadline : November 15th 2024 extended until Friday November 22
URL:https://www.bricbordeaux.com/en/event/neurooncology-meets-neuroscience-symposium/
LOCATION:Institut Broca\, 146 rue leo Saignat\, Bordeaux\, France
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/04/symposium-neuro-oncologie-bordeaux-2024-12-910-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241210T143000
DTEND;TZID=Europe/Paris:20241210T153000
DTSTAMP:20241121T144417Z
CREATED:20241114T114005Z
LAST-MODIFIED:20241121T144417Z
UID:48157-1733841000-1733844600@www.bricbordeaux.com
SUMMARY:BRIC prestige seminar: Jean-Philippe Girard
DESCRIPTION:Jean-Philippe Girard\, Directeur de Recherche INSERM \nCNRS Silver Medal 2013\,\nTeam leader “Biologie Vasculaire: Cellules endothéliales dans l’Immunité\, l’Inflammation et le Cancer”\nIPBS-CNRS (Institut de pharmacologie et de biologie structurale)\, Université de Toulouse\, Toulouse\, France. \nHigh endothelial venules (HEVs) : specialized blood vessels for lymphocyte entry in tumors during cancer immunotherapy \nConference in English.— \nTuesday\, December 10\, 2024\, 2:30 p.m. \nconference room BBS (Bordeaux\, Biologie Santé) 2 rue Dr Hoffmann Martinot – Site Carreire Université de Bordeaux \n  \nKeywords \nTumor microenvironnement\, Tumor-infiltrating lymphocytes\, Cancer immunotherapy \n  \nAbstract \nImmunotherapy\, a therapeutic strategy aimed at increasing the activity of the immune system\, has revolutionized cancer treatment over the past decade. A better understanding of how this therapeutic approach works\, and more particularly how killer lymphocytes access tumors during immunotherapy\, could improve the efficacy of the treatments. We recently discovered the essential role played in this process by specialized blood vessels known as tumor-associated high endothelial venules (TA-HEVs) (Asrir* et al. Cancer Cell 2022). TA-HEVs share important phenotypic and functional characteristics with HEVs in lymph nodes and other lymphoid organs (Moussion and Girard\, Nature 2011 ; Girard et al\, Nature Rev Immunol 2012). For the first time\, we were able to film the lymphocytes infiltrating TA-HEV walls to enter the tumors. We found that increasing the proportion of TA-HEVs in a tumor improves the infiltration of stem-like CD8+ T cells\, the efficacy of the immunotherapy and leads to the eradication of the tumors. Finally\, we showed that the likelihood of recovery of metastatic melanoma patients treated with anti-PD-1 plus anti-CTLA-4 immunotherapy is increased when a large number of TA-HEVs are present in tumors. Together our results suggest that increasing the density of TA-HEVs in human tumors could increase lymphocyte infiltration\, making immunotherapy effective in a greater number of patients.   \n  \nReferences \nAsrir\, A.*\, Tardiveau; C.*\, Coudert\, J.*\, Laffont\, R.*\, Blanchard\, L.*\, Bellard\, E.\, Veerman\, K.\, Bettini\, S.\, Lafouresse\, F.\, Vina\, E.\, Tarroux\, D.\, Roy\, S.\, Girault\, I.\, Molinaro\, I.\, Martins\, F.\, Scoazec\, J.Y.\, Ortega\, N.\, Robert\, C. and Girard\, J.P. (2022) Tumor-associated HEVs mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell\, 40:318-334 (article sélectionné dans ‘Best of Cancer Cell 2022’\, ‘Highly cited article’ du Web of Science; 157 citations dans Google Scholar). \nGirard\, J.P.\, Moussion\, C.\, and Forster\, R. (2012). HEVs\, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 12\, 762-773. \nMoussion\, C.\, and Girard\, J.P. (2011). Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 479\, 542-546. \n  \nBiosketch \nJean-Philippe Girard (PhD) currently holds a position of Senior Research Director at INSERM (French NIH) at IPBS-CNRS\, a large Research Center from the CNRS and the University of Toulouse (France). He received his Ph.D. in Molecular Biology from the University of Toulouse and did his postdoctoral training in Immunology and Vascular Biology at Harvard Medical School (USA) with Pr Tim Springer. Jean-Philippe Girard’s research focuses on the role of high endothelial venules (HEVs) and interleukin-33 (IL-33) in immunity\, inflammation and cancer. He discovered the alarmin cytokine IL-33 as a nuclear factor of HEV (NF-HEV). HEV blood vessels are portals of entry for lymphocytes into lymphoid organs (Moussion and Girard\, Nature 2011; Girard et al\, Nature Rev Immunol 2012). He showed that blood vessels with HEV characteristics designated tumor-associated HEVs are the main sites of lymphocyte entry into tumors\, and are associated with response to immune checkpoint blockade (Asrir* et al Cancer Cell 2022). Dr. Girard is a Highly Cited Researcher in Immunology according to the Web of Science (HCR Index 2023). He received several Scientific Prizes for his work\, including the CNRS Silver Medal (2103)\, and Prizes from the National Academy of Sciences (2012)\, the National Academy of Medecine (2013)\, ‘Fondation pour la Recherche Médicale’ (2016)\, ‘Fondation de France’ (2018) and ‘Fondation ARC’ (2024).       \nJean-Philippe Girard is invited by Team 9 Sarcotarget to sit on the jury for Florent Peyraud’s thesis defense on the same day.
URL:https://www.bricbordeaux.com/en/event/invited-seminar-jean-philippe-girard/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/11/prestige-seminar-jean-philippe-girard.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241213T140000
DTEND;TZID=Europe/Paris:20241213T170000
DTSTAMP:20241212T140913Z
CREATED:20241203T153913Z
LAST-MODIFIED:20241212T140913Z
UID:48321-1734098400-1734109200@www.bricbordeaux.com
SUMMARY:Thesis defense Clément Marcelin\, team 4
DESCRIPTION:Clément Marcelin\, Team 04 – Helicobacter-associated digestive cancers\, cancer stem cells and therapeutic strategies \nThesis director Nicolas Grenier \nPhD specialization: Bioimaging \nTitle : Combinaison de Modèles Expérimentaux et Cliniques pour l’Évaluation de la Thermométrie IRM \nSalle broussin Delorme and visio\nCHU Bordeaux Pellegrin\, Service d’imagerie médicale. \nFriday\, December 13\, 2pm \nJury members: \n\nPr. Vania Tacher\, Hopital Henri-Mondor\, Créteil\, rapporteur\nPr. Julien Frandon\, CHU Nîmes\, rapporteur\nPr. Nicolas Grenier\, Directeur de thèse\nPr. Hélène Vernhet-Kovacsik\, Hôpital Arnaud de Villeneuve\, Montpellier\nDr Eva Jambon\, CHU Bordeaux\n\nNotice of thesis defense at this link.
URL:https://www.bricbordeaux.com/en/event/thesis-defense-clement-marcelin-team-4/
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/12/soutenance-de-these-clement-marcelin-team-4.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241216T123000
DTEND;TZID=Europe/Paris:20241216T170000
DTSTAMP:20241213T111802Z
CREATED:20241213T111802Z
LAST-MODIFIED:20241213T111802Z
UID:48446-1734352200-1734368400@www.bricbordeaux.com
SUMMARY:Mariella Spalato-Ceruso thesis defense - team 9 BRIC
DESCRIPTION:thesis defense Dr Mariella Spalato-Ceruso\, team 9 Sarcotarget \nPhD specialization: Cell Biology and Pathophysiology \nTitle : Profil génomique et immunologique des sarcomes métastatiques des tissus mous. \nMonday\, December 16 – 12:30 p.m. \nMeeting Room 7th floor\nInstitut Bergonié Building G\n229 Cours de l’Argonne 33000 Bordeaux \nNotice of defense at this link
URL:https://www.bricbordeaux.com/en/event/mariella-spalato-ceruso-thesis-defense-team-9-bric/
LOCATION:Institut Bergonié\, 229 Cours de l'Argonne\, Bordeaux\, 33076\, France
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/12/soutenance-de-these-mariella-spalato-team-9.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241220T100000
DTEND;TZID=Europe/Paris:20241220T140000
DTSTAMP:20241212T101800Z
CREATED:20241212T101800Z
LAST-MODIFIED:20241212T101800Z
UID:48363-1734688800-1734703200@www.bricbordeaux.com
SUMMARY:Camille Tocqueville thesis defense - MIRCADE team - BRIC
DESCRIPTION:Camille Tocqueville‘s thesis defense\, team 06 – MIRCADE (Methods and Innovations for Childhood Cancer Research). \nThesis director Philippe VESCHAMBRE \nPhD specialty: Cancer biology. \n“Implication de la Striatin3 dans la régulation des voies Wnt et Hippo dans le carcinome hépatocellulaire et son rôle de suppresseur de tumeur dans l’hépatoblastome” \nFriday\, December 20\, 10 a.m. \nAmphi BBS\, 2 rue du Dr Hoffmann Martinot\, Bordeaux \nNotice of thesis defense at this link
URL:https://www.bricbordeaux.com/en/event/camille-tocqueville-thesis-defense-mircade-team-bric/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/12/soutenance-de-these-camille-tocqueville-bric.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250210T110000
DTEND;TZID=Europe/Paris:20250210T120000
DTSTAMP:20250128T102442Z
CREATED:20250128T101647Z
LAST-MODIFIED:20250128T102442Z
UID:48734-1739185200-1739188800@www.bricbordeaux.com
SUMMARY:Maria Rodriguez-Colman - Team 1 BRIC Invited seminar
DESCRIPTION:Maria Rodriguez-Colman\, PhD. Associate Professor at Center for Molecular Medicine (CMM)\, University Medical Centrum Utrecht (UMC Utrecht)\, The Netherlands\, invited by Lucie Brisson and Thomas Mathivet\, team 1 BRIC.  \n“Driving forces: Metabolism in tumor development dynamics” \nThe Rodriguez Colman Lab investigates the Metabolism of Stem Cells and Cancer. We use organoids as model systems\, heterocellular structures that recapitulate the complexity of in vivo tissue dynamics\, including stem cell differentiation and cellular plasticity. Our research integrates bioenergetics\, metabolomics\, and other omics approaches with cutting-edge 4D live imaging to capture metabolic changes across different scales with high temporal resolution. By genetically introducing fluorescent-based reporters\, we monitor metabolite levels within distinct cellular compartments while simultaneously tracking cell type specification. This long-term live imaging data is analyzed using machine learning-based single-cell tracking coupled with advanced analytical pipelines. In this presentation\, I will discuss our findings on how lactate\, traditionally considered a metabolic waste product of tumors\, plays a regulatory role in cancer stem cell differentiation and plasticity through the epigenetic modulation of oncogenes such as MYC.     \n www.RodriguezColmanLab.org \n 
URL:https://www.bricbordeaux.com/en/event/maria-rodriguez-colman-team-1-bric-invited-seminar/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/01/invited-seminar-maria-rodriguez-colman-2025-02-10.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250318T140000
DTEND;TZID=Europe/Paris:20250318T170000
DTSTAMP:20250224T155724Z
CREATED:20250224T155724Z
LAST-MODIFIED:20250224T155724Z
UID:48924-1742306400-1742317200@www.bricbordeaux.com
SUMMARY:SBM Department thematic seminar "Inflammation in health and diseases"
DESCRIPTION:The Biological and Medical Sciences Department’s (SBM) first thematic seminar of the year 2025 on “Inflammation in Health and Diseases” will be held on Tuesday March 18\, 2025 at 2:00 pm in the amphitheater of the BBS building\, on the Carreire campus. \nAksam Merched\, team 6 BRIC is organizing this seminar with Vanja Sisirak from ImmunoConcept in collaboration with the Department’s Seminar WG. \nSpeakers: \n\nDr. Magnus BACK \, MD\, PhD (Karolinska Institute)\nDr. Emmanuel Laurent GAUTIER \, PhD (Sorbonne University)\n\nIn addition to the main presentations\, we invite doctoral and post-doctoral students to present their work on this theme in a 5-minute “flash presentation” format. \nThe seminar will be followed by a round-table discussion over a convivial drink in the BBS cafeteria. \nWould you like to participate as a speaker (flash presentation) or attend the round table?\nRegister now!
URL:https://www.bricbordeaux.com/en/event/sbm-department-thematic-seminar-inflammation-in-health-and-diseases/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/png:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/02/thematicseminar-18-03-2025.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250319
DTEND;VALUE=DATE:20250322
DTSTAMP:20241219T151854Z
CREATED:20241219T151854Z
LAST-MODIFIED:20241219T151854Z
UID:48530-1742342400-1742601599@www.bricbordeaux.com
SUMMARY:Annual Congress of the French Society for Gene and Cell Therapy (SFTCG)
DESCRIPTION:Annual congress of the French Society for Gene and Cell Therapy (SFTCG)\, organized by François Moreau-Gaudry (team 8\, Biotherapies Génétique et Oncologie -BioGO).\n\n           \n          \n            March 19 to 21\, 2025\n           \n           Agora du Haut Carré\, Talence.   \n          \n            Free registration for students submitting an abstract\n           \n          \n            \n              https://www.sftcg.fr/annual-congress
URL:https://www.bricbordeaux.com/en/event/annual-congress-of-the-french-society-for-gene-and-cell-therapy-sftcg/
LOCATION:Agora du Haut Carré – Université de Bordeaux\, 43 rue Pierre Noailles\, Talence\, France
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/12/colloque-sftcg-2025-03-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250403T120000
DTEND;TZID=Europe/Paris:20250403T130000
DTSTAMP:20250401T100244Z
CREATED:20250331T154329Z
LAST-MODIFIED:20250401T100244Z
UID:49016-1743681600-1743685200@www.bricbordeaux.com
SUMMARY:Leica - Seminar and demonstration of the Confocal Stellaris microscope
DESCRIPTION:LEICA will be at BBS on April 2 and 3\, 2025\, to demonstrate the Confocal Stellaris microscope.\n\n\nClément Laigle\, LEICA Applications Engineer\, will present the various acquisition options at a unit seminar on Thursday April 3\, from 12 noon to 1 pm.\nTo register\, see email sent by Walid Mahfouf on 26/03. If you are not from BRIC\, contact walid.mahfouf@u-bordeaux.fr \nDemo sessions last from 1h to 1h30 and are open to 3 people. You can reserve your slots on the ENT reservation site in the “BBS4-Demo Stellaris” resource family. \n\nLeica contact:\nAndy Tempez\nProduct Specialist Confocal Microscopy\nFrance South\nandy.tempez@leica-microsystems.com\nMobile : +33 6 74 40 34 72
URL:https://www.bricbordeaux.com/en/event/leica-seminar-and-demonstration-of-the-confocal-stellaris-microscope/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/leica-seminaire-avril-2025-bric.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250403T140000
DTEND;TZID=Europe/Paris:20250404T120000
DTSTAMP:20250407T122608Z
CREATED:20250320T165759Z
LAST-MODIFIED:20250407T122608Z
UID:48992-1743688800-1743768000@www.bricbordeaux.com
SUMMARY:Innovation in oncology
DESCRIPTION:Your research could open up new perspectives!\nTechnology transfer is the key to innovation in oncology\, because it brings research advances to patients. How can we transform these scientific discoveries into concrete solutions for patients and society? How can we support you in this process?   \nTo answer these questions\, SATT Aquitaine\, Inserm-Transfert and the BRIC laboratory are organizing an information and exchange session on April 3 and 4\, 2025\, to explore the opportunities for commercialization and better understand the support mechanisms available. \nThis event is aimed at researchers\, engineers and doctoral students who want to find out more about how to get the most out of their work and the opportunities available to them. A unique opportunity to meet and exchange with technology transfer experts and explore new perspectives for your research.  \n \nInformation and contact: \nAndréa Le Brazidec : a.lebrazidec@ast-innovations.com \n\nMore details and registration at this link.\n———————–\nProgram\nThursday\, April 03 – 2pm-5pm: Understand and be inspired!\nLocation: Amphi Centre Broca Nouvelle – Aquitaine – RdC14h00 – Introduction with Frédéric Saltel\, Director of BRIC. \n14h10 – Feedback\nGrégoire Prevost\, entrepreneur in residence at the BRIC Lab\, will highlight the challenges and opportunities of technology transfer identified during his mission. \n\nWhat obstacles have been identified to technology transfer in the lab?\nWhy and how can you add value to your work?\nWhat are the opportunities for oncology research?\n\n15h00 – Innovation support schemes \nSATT Aquitaine and Inserm Transfert will be presenting their support services for researchers. \n\nHow can SATT Aquitaine and Inserm Transfert help you?\nWhat is the relationship between SATT Aquitaine and Inserm Transfert?\nWhat business model for technology transfer?\nA few examples of value-adding in the healthcare sector.\n\n15h50 – The concrete case of a BRIC start-up\nBy Madeleine Moscatelli CEO of BeLiver. \n16h10 – The OncoSTART consortium \nLucia Robert\, coordinator of OncoSTART and CEO of MATWIN\, will present this program dedicated to researchers wishing to enter the field of oncology. \n16h30 – Informal exchange over a snack \n\nFriday\, April 04 – 09h-12h: Taking action!\nLocation: Meeting room S.2040 Est (BBS – Salles R+2)\, on registration09h00 – Workshops: Structuring your oncology project\nTake advantage of Grégoire Prevost’s expertise to work on the positioning and value of your research results\, analyze its strengths\, weaknesses\, opportunities and threats\, and start building a structured action plan. \n\nEvaluate your project with a strategic SWOT analysis.\nDetermine your invention’s Target Product Profile\, used to describe the ideal characteristics of a product prior to development.\nDesign your roadmap to define the steps and milestones you need to reach to bring your project to fruition.
URL:https://www.bricbordeaux.com/en/event/innovation-in-oncology/
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/journee-de-formation-a-la-valorisation--pui-bordeaux-bric-avril-2025.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250415T140000
DTEND;TZID=Europe/Paris:20250415T170000
DTSTAMP:20250317T161408Z
CREATED:20250317T154528Z
LAST-MODIFIED:20250317T161408Z
UID:48931-1744725600-1744736400@www.bricbordeaux.com
SUMMARY:Thesis defense Marine JAUVAIN\, team 4
DESCRIPTION:Defense of thesis in Microbiology – Immunology \nMarine JAUVAIN\, University hospital assistant\nTeam 04 – Helicobacter-associated digestive cancers\, cancer stem cells and therapeutic strategies.\nThesis supervision Émilie BESSEDE \nTuesday\, April 15 – 2pm Amphi BBS (Bordeaux Biologie Santé) site Carreire Université de Bordeaux – 2 rue du Dr Hoffmann Martinot – Bordeaux \n“Étude du microenvironnement bactérien dans le contexte de la carcinogenèse gastrique.”
URL:https://www.bricbordeaux.com/en/event/thesis-defense-marine-jouvain-team-4/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/soutenance-de-these-marine-jauvain-team-4.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250415T140000
DTEND;TZID=Europe/Paris:20250415T170000
DTSTAMP:20250331T133552Z
CREATED:20250317T161656Z
LAST-MODIFIED:20250331T133552Z
UID:48937-1744725600-1744736400@www.bricbordeaux.com
SUMMARY:Thesis defense Marine JAUVAIN\, team 4
DESCRIPTION:Defense of thesis in Microbiology – Immunology \nMarine JAUVAIN\, University hospital assistant\nTeam 04 – Helicobacter-associated digestive cancers\, cancer stem cells and therapeutic strategies.\nThesis supervision Émilie BESSEDE \nTuesday\, April 15 – 2pm Amphi BBS (Bordeaux Biologie Santé) site Carreire Université de Bordeaux – 2 rue du Dr Hoffmann Martinot – Bordeaux \n“Étude du microenvironnement bactérien dans le contexte de la carcinogenèse gastrique.” \nSummary and notice of defense available at this link
URL:https://www.bricbordeaux.com/en/event/thesis-defense-marine-jauvain-team-4/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/soutenance-de-these-marine-jauvain-team-4.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250418T110000
DTEND;TZID=Europe/Paris:20250418T120000
DTSTAMP:20250415T075049Z
CREATED:20250414T093133Z
LAST-MODIFIED:20250415T075049Z
UID:49146-1744974000-1744977600@www.bricbordeaux.com
SUMMARY:Invited seminar Léa Lemaitre - 18-04-2025
DESCRIPTION:Dr Léa Lemaitre \nPost Doc\, Division of Gastroenterology and Hepatology\, Stanford University\, Stanford\, CA\, USA \ninvited by Christophe Grosset\, team 6 MIRCADE\, Methods and Innovations for the Research in Pediatric Cancers. \nTitle: Targeting Macrophage-Mediated Mechanisms of Immune Evasion as adjuvant therapy in TACE-resistant Hepatocellular Carcinoma. \n  \nAbstract: \nA key obstacle to progress in treatment of hepatocellular carcinoma (HCC) is the notorious tenacity of HCC to recur. Transarterial chemoembolization (TACE) is the most common treatment for unresectable HCC\, however\, it fails to provide a durable cure. The crux of the problem lies in residual cancer cells that persist after TACE. Our goal is to understand how these residual cells escape immune detection and survive after TACE in order to develop effective adjuvant therapies.    \nWe used both in vitro and in vivo methods to mimic TACE- resistance by generating doxorubicin resistant- residual HCC models. We performed single-cell RNA sequencing on 3D tumoroids (31\,000 cells) of doxorubicin resistant vs control HCC in coculture with macrophages. In addition\, HCC patient-derived tumor cells and macrophages were used for validation. We developed an immunocompetent mouse model of syngeneic orthotopic allograft model of HCC\, using doxorubicin-resistant or control HCC cell lines to test adjuvant therapies.    \nUsing scRNAseq of 3D tumoroid model\, we show that doxorubicin-resistant cancer cells exhibit a stem-cell-like phenotype with high expression of stemness markers (CK19\, CD44)\, TGFb pathway (TGFBR1) and cytokines driving pro- tumor macrophage polarization (CXCL8\, CCL2). On the other hand\, the macrophages co-cultured with doxorubicin-resistant HCC showed a pro-tumor phenotype with increased PDL1 expression. We validated this finding using patient-derived samples\, showing that doxorubicin resistant HCC tumoroid co- culture increased PDL1 expression on macrophages. Further\, mRNA FISH showed that the CD68+ macrophages expressed higher levels of TGFB1 in TACE-resistant HCC than primary HCC (p=0.0011). Based on our in vitro analysis we identified the TGFB pathway and PDL1 as potential synergistic targets for adjuvant therapy of TACE-resistant HCC. In our mouse model of doxorubicin-resistant orthotopic allografts\, we showed that treatment with combined TgfbrI and anti-Pdl1 antibodies resulted in significantly reduced liver tumor burden (p=0.01). Flow cytometry analysis revealed immune remodeling with increased infiltration of CD8T cells and M1-like macrophage (CD86+/MHC- II+)\, along with depletion of macrophages (PDL1+/CD206+) in the liver of treated doxorubicin-resistant orthotopic allografts.       \nWe generated in vitro 3D models of TACE-resistance in HCC and identified the mechanistic roles of the PDL1+ macrophage-derived TGFβ1 on stem-like cancer cell persistence. We developed a mouse model of doxorubicin-resistant HCC and demonstrated that combined targeting of Pdl1 and Tgfb1 blocks tumor progression and evokes and anti-tumor macrophage and CD8T cell immune response. Thus combined targeting of PDL1 and TGFB1 holds therapeutic potential as adjuvant therapy in TACE to eliminate residual HCC\, reduce recurrence and improve patient outcomes in HCC.   \n  \nBiosketch: \nMy long-term research goals are to improve immunotherapies for cancer treatment. My objective is to decipher the complexity of the immune system in the tumor microenvironment. My academic training as a pharmacist and research scientist provides me with a strong background in pharmacy\, medicine\, clinical research\, immunology\, and oncology.   \nIn my first year of pharmacy residency\, I was involved in clinical trials\, and I developed a novel chromatographic method to detect errors in the administration of intravenous chemotherapy. During my residency\, I developed a strong interest in oncology research leading me to pursue an integrated masters program under the mentorship of Dr. Bettina Couderc. I analyzed the crosstalk between macrophages and mesenchymal stromal cells (MSCs) in chemotherapy-resistant ovarian cancer leading to 3 co-author publications. This research project reinforced my passion for immune-oncology. To further understand the role of MSCs in cancer resistance to therapies\, I pursued PhD training under the supervision of Dr. Bettina Couderc and Jill Corre\, entitled “Phenotypic and functional characterization of cancer-associated MSCs in multiple myeloma”. This work advanced the understanding of the tumor microenvironment in multiple myeloma and led to the publication of two first-authored publications (1\, 2). During my doctoral and postdoctoral training\, I was also involved in another project to decipher mechanisms of resistance to immunotherapy\, the results were published in Immunity with me as the second author (3). I thus gained strong training and expertise in tumor immunology and novel immune monitoring technologies.          \nThree years ago\, I joined the Dhanasekaran Lab to deepen my expertise in immuno-oncology. I have gained proficiency in advanced technologies such as CyTOF\, spatial immunology and organoids. I have published a manuscript discussing macrophage-mediated mechanisms of resistance to immune checkpoint inhibitors (4\, co-author\, Cancer Res\, 2023) and an article identifying novel mechanisms of resistance to therapy in liver cancer (5\, first author\, Nat Cancer\, 2024). These papers serve as a cornerstone for my current application to develop a precision oncology platform for immunotherapy in HCC. Alongside my mentor\, I have crafted a comprehensive career development plan aimed at enhancing my abilities in grant writing\, mentoring\, teaching\, and communication.     \n  \n\nLea Lemaitre\, DoSouto Ferreira L\, Joubert MV\, Avet-Loiseau H\, Martinet L\, Corre J\, Couderc Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma. Int J Mol Sci. 2020 May 28.  \nLea Lemaitre\, Hamaidia M\, Descamps JG\, Do Souto Ferreira L\, Joubert MV\, Gadelorge M\, Avet-Loiseau H\, Justo A\, Reina N\, Deschaseaux F\, Martinet L\, Bourin P\, Corre J\, Espagnolle N. Toll-like receptor 4 selective inhibition in medullary microenvironment alters multiple myeloma cell growth. Blood advance. 2022 Jan 25; 6(2):672-678.  \nWeulersse M*\, Asrir A*\, Pichler AC*\, Lemaitre Lea\, Braun M\, Carrié N\, Joubert MV\, Le Moine M\, Do Souto L\, Gaud G\, Das I\, Brauns E\, Scarlata CM\, Morandi E\, Sundarrajan A\, Cuisinier M\, Buisson L\, Maheo S\, Kassem S\, Agesta A\, Pérès M\, Verhoeyen E\, Martinez A\, Mazieres J\, Dupré L\, Gossye T\, Pancaldi V\, Guillerey C\, Ayyoub M\, Dejean AS\, Saoudi A\, Goriely S\, Avet-Loiseau H\, Bald T\, Smyth MJ\, Martinet L.. ** co-authors. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8 + T Cell Anti- tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity. 2020 Oct 13.\nRenumathy Dhanasekaran\, Aida Hansen\, Jangho Park\, Lea Lemaitre\, Nia Adeniji\, Sibu Kuruvilla\, Akanksha Suresh\, Josephine Zhang\, Varsha Swamy\, Dean W. Felsher. MYC overexpression drives immune evasion in hepatocellular carcinoma (HCC) that is reversible through restoration of pro- inflammatory macrophages. Cancer research. 2022 Dec 16.   \nLea Lemaitre*\, Nia Adeniji*\, Akanksha Suresh*\, Reshma Reguram\, Josephine Zhang\, Jangho Park\, Amit Reddy\, Alexandro E. Trevino\, Aaron T. Mayer\, Anja Deutzmann\, Aida Hansen\, Ling Tong\, Vinodhini Arjunan\, Neeraja Kambham\, Brendan Visser\, Monica Dua\, Andrew Bonham\, Nishita Kothary\, H. Blaize D’Angio\, Ryan Preska\, Yanay Rosen\, James Zou\, Vivek Charu\, Dean W. Felsher and Renumathy Dhanasekaran. Spatial Analysis Reveals Targetable Macrophage-Mediated Mechanisms of Immune Evasion in Hepatocellular Carcinoma Minimal Residual Disease. Nature cancer. 2024 Sept 20
URL:https://www.bricbordeaux.com/en/event/invited-seminar-lea-lemaitre-18-04-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/seminar-lea-lemaitre-2025-04-18.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250513T093000
DTEND;TZID=Europe/Paris:20250513T103000
DTSTAMP:20250428T132916Z
CREATED:20250422T144410Z
LAST-MODIFIED:20250428T132916Z
UID:49188-1747128600-1747132200@www.bricbordeaux.com
SUMMARY:Invited Seminar Bruno Segui -13-05-2025
DESCRIPTION:Pr. Bruno Segui \, invited by Majid Khatib\, team 2 Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme).\nCo-head of the team MELASPHINX: Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in the Toulouse Cancer Research Center (CRCT) \nTitle : TNF blockade with certolizumab\, but not infliximab\, improves efficacy of anti-PD-1 and anti-CTLA-4 combination in melanoma \n  \nAbstract \nThe combination of anti-PD-1 and anti-CTLA-4 boosts the anti-cancer immune response in patients with advanced melanoma. However\, 60% of patients fail to respond or relapse early after induction\, and 95% develop immune-related adverse events (irAEs) such as colitis\, which can be treated with infliximab\, a tumour necrosis factor-alpha inhibitor (TNFi). The impact of TNFi on immune and clinical responses remains to be elucidated. Here we provide evidence that TNF blockade can improve the response to the anti-PD-1 and anti-CTLA-4 combination not only in mice but also in patients enrolled in a phase 1b clinical trial (TICIMEL\, NTC03293784). However\, certolizumab\, but not infliximab\, strongly stimulates immune and therapeutic responses to ICI. Mechanistically\, we have shown that the IgG1 Fc fragment of infliximab impairs the ability of TNF blockade to stimulate the efficacy of ICI therapy. When combined with ICI\, certolizumab decreased the proportion of regulatory T cells (Tregs) and exhausted T cells\, while increasing the proportion of effector T cells in tumors as assessed by single-cell RNA sequencing and spectral flow cytometry. In conclusion\, our study shows that TNF impairs the immune response to melanoma and that the type of TNFi must be well selected to improve the efficacy of ICI in melanoma.        \n  \nBruno Ségui  \nCV overview: \n2000: PhD in human pathophysiology (Toulouse University). \n2000-2002: Postdoctoral position (University College London\, UK). \n2006: HDR (Toulouse University). \n2002-2011: Assistant Professor of Immunology\, Faculty of Pharmacy (Toulouse III). \nSince 2011: Professor of Cell Biology\, Faculty of Pharmacy (Toulouse III). \nResearch activity in the Cancer Research Center of Toulouse (CRCT). \nSince 2019: Deputy Director of the CARe graduate school on Cancer Aging and Rejuvenation. \nSince 2021: Team leader of MELASPHINX at the Cancer Research Center of Toulouse\, \nco-PI: Dr. N. Andrieu-Abadie.  \n  \nOverview of research activities: \nOver the last 25 years\, I have been studying the signalling pathways triggered by some members of the TNF receptor superfamily\, including CD40\, Fas/CD95 and TNFR1/CD120a. In this context\, we have highlighted the role of sphingolipids in the modulation of both apoptosis and immune responses (Ségui et al.\, J. Biol. Chem.\, 1999; Ségui et al\, J. Clin. Invest. 2001; Montfort et al.\, J. Immunol. 2009; Lafont et al.\, Cell Death Differ. 2010). More recently\, we have shown that TNF blockade enhances the CD8 T cell-dependent immune response (Bertrand et al.\, Cancer Res. 2015) and overcomes the resistance to anti-PD-1 (Bertrand et al.\, Nat. Commun. 2017) in mouse melanoma models. Mechanistically\, TNF triggers the activation-induced cell death of CD8+ tumour-infiltrating lymphocytes. We have translated our concept into the clinic in advanced melanoma patients\, where we have shown that two triple therapies combining TNF blockers (infliximab or certolizumab) with anti-PD-1 (nivolumab) and anti-CTLA-4 (certolizumab) are safe for patients\, with promising signs of efficacy in the certolizumab cohort (Montfort et al.\, Clin. Cancer Res 2021). Moreover\, Elevated plasma TNF and enriched TNF pathways in T cells are associated with poorer clinical outcome in patients with advanced melanoma\, reinforcing the notion that TNF may dampen the efficacy of immune checkpoint inhibitors (Virazels et al.\, Int J Cancer\, in press).      \n 
URL:https://www.bricbordeaux.com/en/event/invited-seminar-bruno-segui-12-05-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/seminar-bruno-segui-2025-05-13.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250513T093000
DTEND;TZID=Europe/Paris:20250513T103000
DTSTAMP:20250428T133528Z
CREATED:20250428T133528Z
LAST-MODIFIED:20250428T133528Z
UID:49259-1747128600-1747132200@www.bricbordeaux.com
SUMMARY:Invited Seminar - Bruno Segui - 13-05-2025
DESCRIPTION:Pr. Bruno Segui \, invited by Majid Khatib\, team 2 Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme).\nCo-head of the team MELASPHINX: Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in the Toulouse Cancer Research Center (CRCT) \nTitle : TNF blockade with certolizumab\, but not infliximab\, improves efficacy of anti-PD-1 and anti-CTLA-4 combination in melanoma \n  \nAbstract \nThe combination of anti-PD-1 and anti-CTLA-4 boosts the anti-cancer immune response in patients with advanced melanoma. However\, 60% of patients fail to respond or relapse early after induction\, and 95% develop immune-related adverse events (irAEs) such as colitis\, which can be treated with infliximab\, a tumour necrosis factor-alpha inhibitor (TNFi). The impact of TNFi on immune and clinical responses remains to be elucidated. Here we provide evidence that TNF blockade can improve the response to the anti-PD-1 and anti-CTLA-4 combination not only in mice but also in patients enrolled in a phase 1b clinical trial (TICIMEL\, NTC03293784). However\, certolizumab\, but not infliximab\, strongly stimulates immune and therapeutic responses to ICI. Mechanistically\, we have shown that the IgG1 Fc fragment of infliximab impairs the ability of TNF blockade to stimulate the efficacy of ICI therapy. When combined with ICI\, certolizumab decreased the proportion of regulatory T cells (Tregs) and exhausted T cells\, while increasing the proportion of effector T cells in tumors as assessed by single-cell RNA sequencing and spectral flow cytometry. In conclusion\, our study shows that TNF impairs the immune response to melanoma and that the type of TNFi must be well selected to improve the efficacy of ICI in melanoma.        \n  \n📆 Tuesday\, May 13 9:30 a.m.\n📌 Amphi BBS (Bordeaux Biologie Santé) 2 rue du Dr Hoffmann Martinot \n  \nBruno Ségui  \nCV overview: \n2000: PhD in human pathophysiology (Toulouse University). \n2000-2002: Postdoctoral position (University College London\, UK). \n2006: HDR (Toulouse University). \n2002-2011: Assistant Professor of Immunology\, Faculty of Pharmacy (Toulouse III). \nSince 2011: Professor of Cell Biology\, Faculty of Pharmacy (Toulouse III). \nResearch activity in the Cancer Research Center of Toulouse (CRCT). \nSince 2019: Deputy Director of the CARe graduate school on Cancer Aging and Rejuvenation. \nSince 2021: Team leader of MELASPHINX at the Cancer Research Center of Toulouse\, \nco-PI: Dr. N. Andrieu-Abadie.  \n  \nOverview of research activities: \nOver the last 25 years\, I have been studying the signalling pathways triggered by some members of the TNF receptor superfamily\, including CD40\, Fas/CD95 and TNFR1/CD120a. In this context\, we have highlighted the role of sphingolipids in the modulation of both apoptosis and immune responses (Ségui et al.\, J. Biol. Chem.\, 1999; Ségui et al\, J. Clin. Invest. 2001; Montfort et al.\, J. Immunol. 2009; Lafont et al.\, Cell Death Differ. 2010). More recently\, we have shown that TNF blockade enhances the CD8 T cell-dependent immune response (Bertrand et al.\, Cancer Res. 2015) and overcomes the resistance to anti-PD-1 (Bertrand et al.\, Nat. Commun. 2017) in mouse melanoma models. Mechanistically\, TNF triggers the activation-induced cell death of CD8+ tumour-infiltrating lymphocytes. We have translated our concept into the clinic in advanced melanoma patients\, where we have shown that two triple therapies combining TNF blockers (infliximab or certolizumab) with anti-PD-1 (nivolumab) and anti-CTLA-4 (certolizumab) are safe for patients\, with promising signs of efficacy in the certolizumab cohort (Montfort et al.\, Clin. Cancer Res 2021). Moreover\, Elevated plasma TNF and enriched TNF pathways in T cells are associated with poorer clinical outcome in patients with advanced melanoma\, reinforcing the notion that TNF may dampen the efficacy of immune checkpoint inhibitors (Virazels et al.\, Int J Cancer\, in press).      \n 
URL:https://www.bricbordeaux.com/en/event/invited-seminar-bruno-segui-13-05-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/seminar-bruno-segui-2025-05-13.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250514T150000
DTEND;TZID=Europe/Paris:20250514T160000
DTSTAMP:20250428T092433Z
CREATED:20250428T092433Z
LAST-MODIFIED:20250428T092433Z
UID:49248-1747234800-1747238400@www.bricbordeaux.com
SUMMARY:Invited seminar - Thomas Bertero - 14-05-2025
DESCRIPTION:Invited seminar by Violaine Moreau\, Team 3\, Liver Cancers and Tumor Invasion and Isabelle Sagot\, Quiessence and Multicellularity Team\, IBGC \nThomas Bertero is CRCN CNRS\, CNRS Bronze Medal 2019. He studies the link between the mechanical response of cells to their environment and metabolism.\nInstitut de Pharmacologie moléculaire et cellulaire (IPMC)\nUniversité Côte d’Azur/CNRS/Inserm\nValbonne \nTitle: Mechano-metabolism: From tissues to molecules\n\nAbstract :\nThe spatiotemporal control of cell behaviour requires the transmission of information from the complex structure of tissues to their constituent cells. Mechanotransduction enables this transmission by sensing mechanical environments and adapting cellular behaviours. However\, this process requires energy. Since our pioneering study demonstrating a link between cell mechanics and cell metabolism (Bertero et al\, J Clin Invest 2016) our laboratory has been interested in deciphering how tissue mechanical properties shape – and are shaped by – cell metabolism. Here\, I will summarise our recent discoveries on how the mechanical properties of the tumour niche reprogram glutamine and glucose metabolism to promote breast cancer progression.    \n📆 Wednesday\, May 14\, 3pm\n📌 Amphi BBS (Bordeaux Biologie Santé) 2 rue du Dr Hoffmann Martinot \nSelected publications:\nMechano-dependent sorbitol accumulation supports biomolecular condensate. \nTorrino S\, Oldham WM\, Tejedor AR\, Burgos IS\, Nasr L\, Rachedi N\, Fraissard K\, Chauvet C\, Sbai C\, O’Hara BP\, Abélanet S\, Brau F\, Favard C\, Clavel S\, Collepardo-Guevara R\, Espinosa JR\, Ben-Sahra I\, Bertero T. Cell. 2025 Jan 23;188(2):447-464.e20. doi: 10.1016/j.cell.2024.10.048.   \n\n \nSystems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. \nBertero T\, Lu Y\, Annis S\, Hale A\, Bhat B\, Saggar R\, Saggar R\, Wallace WD\, Ross DJ\, Vargas SO\, Graham BB\, Kumar R\, Black SM\, Fratz S\, Fineman JR\, West JD\, Haley KJ\, Waxman AB\, Chau BN\, Cottrill KA\, Chan SY. J Clin Invest. 2022 May 16;132(10):e161077. doi: 10.1172/JCI161077.  \n\n \n\n\nMetabo-reciprocity in cell mechanics: feeling the demands/feeding the demand. \nTorrino S\, Bertero T. Trends Cell Biol. 2022 Jul;32(7):624-636. doi: 10.1016/j.tcb.2022.01.013. Epub 2022 Feb 14.   \n \nMechano-induced cell metabolism promotes microtubule glutamylation to force metastasis. \nTorrino S\, Grasset EM\, Audebert S\, Belhadj I\, Lacoux C\, Haynes M\, Pisano S\, Abélanet S\, Brau F\, Chan SY\, Mari B\, Oldham WM\, Ewald AJ\, Bertero T. Cell Metab. 2021 Jul 6;33(7):1342-1357.e10. doi: 10.1016/j.cmet.2021.05.009.  \n \n\n\nTumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy. \nBertero T\, Oldham WM\, Grasset EM\, Bourget I\, Boulter E\, Pisano S\, Hofman P\, Bellvert F\, Meneguzzi G\, Bulavin DV\, Estrach S\, Feral CC\, Chan SY\, Bozec A\, Gaggioli C. Cell Metab. 2019 Jan 8;29(1):124-140.e10. doi: 10.1016/j.cmet.2018.09.012.  \n \nVascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. \nBertero T\, Oldham WM\, Cottrill KA\, Pisano S\, Vanderpool RR\, Yu Q\, Zhao J\, Tai Y\, Tang Y\, Zhang YY\, Rehman S\, Sugahara M\, Qi Z\, Gorcsan J 3rd\, Vargas SO\, Saggar R\, Saggar R\, Wallace WD\, Ross DJ\, Haley KJ\, Waxman AB\, Parikh VN\, De Marco T\, Hsue PY\, Morris A\, Simon MA\, Norris KA\, Gaggioli C\, Loscalzo J\, Fessel J\, Chan SY. J Clin Invest. 2016 Sep 1;126(9):3313-35. doi: 10.1172/JCI86387.
URL:https://www.bricbordeaux.com/en/event/invited-seminar-thomas-bertero-14-05-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/thomas-bertero-2025-05-14.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250517T100000
DTEND;TZID=Europe/Paris:20250517T163000
DTSTAMP:20250612T092854Z
CREATED:20250512T092937Z
LAST-MODIFIED:20250612T092854Z
UID:49521-1747476000-1747499400@www.bricbordeaux.com
SUMMARY:2025 Brain Cancer Open House Day
DESCRIPTION:As part of Brain Cancer Awareness Month\, the BRIC is once again organizing its Open House Day on Saturday\, May 17\, 2025\, from 10:00 AM to 4:30 PM\, at its facilities located in Pessac\, on the François Bordes campus (Building B2). \nThis initiative\, fully aligned with the goal of science outreach\, aims to introduce the general public to the daily life of researchers and recent advances in brain cancer research — through engaging\, accessible formats. \nThis free event\, open to everyone\, will feature:\nGuided tours of part of the BRIC’s research labs\nInformation stations with simplified posters\, presented by researchers from Team 1\nMini-seminars\nDiscussions with scientists\, healthcare professionals\, and patient advocacy groups\, including: \nParticipating associations:La Ligue contre le cancer\, Des Étoiles dans la Mer\, ARTC (Association for Brain Tumor Research)\, and ADAM (Association for Children with Medulloblastoma). \nThis initiative is led by Team 1 of the BRIC\, in collaboration with its institutional sponsors (Inserm\, University of Bordeaux\, CNRS) and scientific partners (IBGC and GBMetabo). \n📍 Access: Tram B (François Bordes or Doyen Brus stops) – Free parking nearby (Avenue Léon Duguit\, Pessac)
URL:https://www.bricbordeaux.com/en/event/2025-brain-cancer-open-house-day/
LOCATION:Bâtiment B2\, Allée Geoffroy Saint-Hilaire\, PESSAC\, 33600\, France
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/05/portes-ouvertes-17-mai.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250612T101500
DTEND;TZID=Europe/Paris:20250612T111500
DTSTAMP:20250523T091324Z
CREATED:20250407T123707Z
LAST-MODIFIED:20250523T091324Z
UID:49045-1749723300-1749726900@www.bricbordeaux.com
SUMMARY:Invited seminar - Romain PARENT - 12-06-2025
DESCRIPTION:Invited seminar by team 6 MIRCADE (Methods and Innovations for the Research in Pediatric Cancers.) headed by Christophe Grosset. \nRomain PARENT\nHepatitis Viruses & Liver Pathogenesis (PathLiv) Laboratory – UMR 1350\nInserm – Claude Bernard Lyon 1 University – Lyon Hepatology Institute \nThe interest of liver innervation in chronic liver disease and liver cancer. \nAbstract\nHepatocellular carcinoma (HCC) care has long been hampered by the enigmatic nature of disease onset across patients\, evolution\, as well as of response or resistance to treatment. Hepatic neural cells are likely the least studied liver cell type and mediate patients singularities from the ANS to the organ in real-time. These cells\, belonging to the autonomic nervous system (ANS)\, mediate liver/whole body crosstalk. Pathological innervation of the ANS has been identified in cancer\, nurturing tumor stroma and conferring stronger carcinogenic properties.\nIn this presentation focusing on a pathogenic continuum between normal liver and HCC\, we will present evidence for: (i) deep alterations of neural markers along this spectrum\, (ii) the presence of neural pools of cells in lesions\, (iii) the introduction of a novel neuronal score-based approach for stratification with respect to pathological and immunological considerations\, and (iv) functional studies causally demonstrating the interest of these notions for rational and accessible therapeutic intervention.     \n  \nBiography\nI obtained a PharmD at the U. of Aix-Marseille 1 in 2001 and a PhD in hepatic virology in 2004 through a PhD exchange program between the Center for the Study of Hepatitis C at the Rockefeller University of New-York and the Inserm Unit 271 in Lyon\, working on the early HCV tissue culture systems.\nI then spent four years at the Fred Hutchinson Cancer Research Center in Seattle working on HCV virology and cell translation. I obtained an Inserm CR2 position in 2009.\nI have been till then leading an independent group within Fabien Zoulim’s PathLiv laboratory\, gradually evolving from translational virology towards the study of liver innervation in pathology\, through a long term work on the axonal guidance cue netrin-1.\nMy group’s work on netrin-1 have ended up in the Phase III HCC-NET1 clinical trial which has for goal to target the axonal guidance factor netrin-1 in HCC. I recently obtained a Master degree in philosophy. As a teaching unit head at the Oncology Master of Lyon 1\, I also tackle these issues through the mind-body philosophical paradigm with the students.   \n 
URL:https://www.bricbordeaux.com/en/event/invited-seminar-romain-parent-12-06-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/invited-seminar-romain-parent-2025-06-12.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250617T120000
DTEND;TZID=Europe/Paris:20250617T130000
DTSTAMP:20250602T131305Z
CREATED:20250602T131305Z
LAST-MODIFIED:20250602T131305Z
UID:49520-1750161600-1750165200@www.bricbordeaux.com
SUMMARY:Webinar “L’Heure Heka”: How Can You Tell If Research Results Have Innovation Potential?
DESCRIPTION:L’Heure Heka is a webinar series dedicated to the intersection of research\, innovation\, and impact. It is organized by SATT Aquitaine Science Transfert as part of the Pôles Universitaires d’Innovation (University Innovation Clusters): Bordeaux\, Sud-Aquitaine Innovation\, and Open Campus Innov. \n________________________________________________________________________ \nThe BRIC is in the spotlight for this 8th edition of L’Heure Heka. \nWhat are the early indicators that suggest a project has strong valorization potential?\nWhat obstacles do researchers face?\nWhat do researchers expect from early-stage support? \nOn Tuesday\, June 17\, 2025\, join us for a discussion on the valorization of research\, using the BRIC as a case study. But this isn’t just about healthcare!\nTogether with Grégoire PREVOST\, CEO of CIPREVO\, and Frédéric SALTEL\, Director of the BRIC\, we’ll explore the levers that help translate innovation from the lab into real-world impact. \nGrégoire PREVOST will share his insights from his experience as a “PUI Entrepreneur-in-Residence\,” a role he held for six months within the BRIC to raise awareness\, structure\, and support high-potential research projects. \nFrédéric SALTEL will provide his perspective as Director of the BRIC on the challenges and opportunities of such an approach. \n\nRegister here: https://blog.ast-innovations.com/fr/heure-heka
URL:https://www.bricbordeaux.com/en/event/webinar-lheure-heka-how-can-you-tell-if-research-results-have-innovation-potential/
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/webp:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/heure-heka-8-1.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250630T110000
DTEND;TZID=Europe/Paris:20250630T120000
DTSTAMP:20250617T140511Z
CREATED:20250617T140511Z
LAST-MODIFIED:20250617T140511Z
UID:49572-1751281200-1751284800@www.bricbordeaux.com
SUMMARY:Invited seminar - Jean-François Côté - 30-06-2025
DESCRIPTION:BRIC Team 3\, Liver Cancers and Tumor Invasion\, co-directed by Violaine Moreau and Frederic Saltel\, is pleased to invite Jean-François Côté\, President and Scientific Director of the Institut de recherches cliniques de Montréal (IRCM)\, Canada\, to present a seminar open to the scientific community.\nJean-François Côté is co-supervisor of Mélissa Correia De Oliveira‘s thesis\, team 3 BRIC. \n\nTitle : Mechanistic Insights into Tumour Growth\, Metastasis\, and Dormancy in Cancer Progression.\n\n\nAbstract\n\nMetastasis is the primary cause of cancer-related deaths\, yet the biological processes that enable tumor cells to spread\, survive in distant organs\, and eventually form secondary tumors remain incompletely understood. Gaining insight into these mechanisms is essential for developing strategies to prevent and treat metastatic disease across cancer types. \nIn the first part of my presentation\, I will discuss tumour dormancy in breast cancer. To uncover regulators of dormancy\, genome-wide CRISPR screens were performed on two breast cancer cell lines: 4T1 (short dormancy) and 4T07 (prolonged dormancy). 4T07 cells uniquely depended on class III PI3K (PIK3C3) and showed elevated mTORC1 activity via peripheral lysosome signaling. Inhibiting PIK3C3 suppressed this activity in both mouse and human models\, reduced metastasis in 4T07\, and eliminated dormant cells in a HER2-driven model. These results highlight PIK3C3-mTORC1 signaling as a potential therapeutic target to prevent metastatic relapse. In the second part of the presentation\, I will focus on RAS family proteins that regulates key signaling pathways involved in cell growth\, differentiation\, and survival. While canonical RAS proteins are well studied\, the broader group of 35 human RAS-related GTPases remains largely unexplored. Using proximity-dependent biotinylation (BioID) in three cell models\, we mapped interaction networks and subcellular localizations across the family. This generated a high-confidence interactome\, revealing thousands of spatially resolved associations. By analyzing nucleotide-state-specific variants\, we identified context-dependent interactions with effectors and regulators. Comparative clustering highlighted conserved and unique features across subfamilies. Integration with DepMap data uncovered essential crosstalk with regulators Rho GTPases and cytoskeletal dynamics in canonical RAS proteins. This resource advances our understanding of RAS-family signaling and its roles in development\, disease\, and cancer.            \n\n\n📆 Monday\, June 30\, 2025\, 11 a.m.\n📌 Conference room BBS (Bordeaux\, Biologie\, Santé)\,\n2 rue dr Hoffmann Martinot\, Bordeaux. Université de Bordeaux\, site Carreire
URL:https://www.bricbordeaux.com/en/event/invited-seminar-jean-francois-cote-30-06-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/jean-francois-cote-2025-06-30.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250702T100000
DTEND;TZID=Europe/Paris:20250702T130000
DTSTAMP:20250627T075338Z
CREATED:20250602T095142Z
LAST-MODIFIED:20250627T075338Z
UID:49523-1751450400-1751461200@www.bricbordeaux.com
SUMMARY:HDR Defense – Thomas MATHIVET
DESCRIPTION:HDR Defense (Accreditation to Supervise Research) in Life and Health Sciences \nThomas Mathivet Team 01 – Tumor and Vascular Biology Laboratory \n“Les molécules de guidage : de l’angiogenèse à la dynamique stromale et à l’invasion des tumeurs cérébrales” \nWednesday\, July 2\, 2025 at 10:00 AM \nBBS Amphitheater\, 2 rue Dr H. Martinot\, Bordeaux (Carreire Campus) \nJury \n➢ M Eric CHEVET\, Directeur de recherche\, Biosit\, INSERM – Rapporteur\n➢ Mme Barbara GARMY-SUSINI\, Directrice de recherche\, I2MC\, INSERM – Rapporteure\n➢ Mme Anna-Rita CANTELMO\, Chargée de recherche\, Université de Lille – Rapporteure\n➢ M François MOISAN\, Docteur\, Université de Bordeaux – Examinateur\n➢ M Andreas BIKALVI\, Professeur des universités\, Université de Bordeaux – Examinateur
URL:https://www.bricbordeaux.com/en/event/hdr-defense-thomas-mathivet/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/soutenance-hdr-thomas-mathivet-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250704T110000
DTEND;TZID=Europe/Paris:20250704T120000
DTSTAMP:20250522T081608Z
CREATED:20250522T081608Z
LAST-MODIFIED:20250522T081608Z
UID:49391-1751626800-1751630400@www.bricbordeaux.com
SUMMARY:Invited seminar - Adriano Sabino - 04-07-2025
DESCRIPTION:Pr Adriano Sabino is invited by Vanessa Desplat\, Team 10\, Normal and Leukemic Hematopoietic Stem Cells. \nTitle: Omics Sciences Applied to the Investigation of Potential Biomarkers and Therapeutic Targets in Acute Leukemias \nPresenter: Prof. Adriano de Paula Sabino – Federal University of Minas Gerais (UFMG)\, Brazil  \nBio: Associate Professor at the Federal University of Minas Gerais (UFMG)\, Brazil. Holds a Ph.D. in Pharmaceutical Sciences with postdoctoral training in cancer therapy resistance at Michigan State University. Academic and research expertise in Clinical\, Experimental\, and Molecular Hematology. Research interests encompass cancer biology\, acute and chronic leukemias\, chemotherapy resistance\, molecular and cellular biomarkers\, functional genomics\, proteomics\, metabolomics\, nanobiomaterials\, regenerative medicine\, cell-based therapies\, and the application of bioinformatics to precision medicine.     \nAbstract: \nAcute leukemias\, including Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)\, are aggressive hematologic malignancies with high biological heterogeneity and limited predictive tools for therapeutic response and disease progression. In this context\, omics sciences offer powerful strategies to unravel the molecular complexity underlying these diseases and support the identification of new biomarkers and therapeutic targets.  \nThis seminar will provide an overview of our translational research efforts combining metabolomics\, clinical peptidomics\, and machine learning. We will discuss the conceptual and methodological foundations for applying mass spectrometry-based omics approaches (LC-MS and MALDI-TOF/MS) to plasma samples\, as well as the integration of artificial intelligence algorithms to enhance biomarker discovery\, risk stratification\, and individualized therapeutic guidance.  \nAdditionally\, we present the rationale and design of predictive modeling studies employing clinical and genomic datasets from AML patients. These models\, based on supervised learning techniques\, aim to improve the accuracy of outcome prediction and inform precision oncology strategies.  \nOur interdisciplinary approach highlights the potential of integrating systems biology\, data science\, and clinical research to advance personalized medicine in oncohematology. \nKeywords: Acute leukemia\, ALL\, AML\, biomarkers\, omics sciences\, LC-MS\, MALDI-TOF/MS\, machine learning\, precision oncology\, clinical stratification. \n📆 Friday 04-07\, 11am \n📌 BBS conference room\, 2 rue Dr Hoffmann Martinot Bordeaux
URL:https://www.bricbordeaux.com/en/event/invited-seminar-adriano-sabino-04-07-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/05/seminar-adriano-sabino-2025-07-13.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250708
DTEND;VALUE=DATE:20250712
DTSTAMP:20250605T085034Z
CREATED:20250605T085034Z
LAST-MODIFIED:20250605T085034Z
UID:49524-1751932800-1752278399@www.bricbordeaux.com
SUMMARY:JOBIM 2025 – Open Days in Biology\, Informatics\, and Mathematics
DESCRIPTION:From July 8 to 11\, 2025\, Bordeaux will host the 2025 edition of JOBIM (Journées Ouvertes en Biologie\, Informatique et Mathématiques) — a major event for the French-speaking bioinformatics community. This year’s conference will take place at LaBRI (Bordeaux Computer Science Research Laboratory)\, bringing together researchers\, engineers\, PhD students\, and professionals from both digital and life sciences to explore the latest developments in the field.  \nThrough the ODIL unit (Omics Data Integration & visuaLization)\, BRIC’s internal bioinformatics cell\, two of our members are currently part of the event’s organizing committee: \n\nCyril Dourthe\, bioinformatics research engineer (BRIC and OncoProt platform)\nÉlodie Darbo\, research engineer in Team 7 – Targeting Transcription in Breast Cancer\n\nTheir involvement reflects the growing role of bioinformatics in oncology research\, particularly in the work carried out within our laboratory\, where the analysis of large-scale data from RNA-seq\, epigenomics\, and cell modeling has become an essential foundation. \nHeld at the crossroads of biology\, mathematics\, and computer science\, the JOBIM conference offers a rich program of talks\, workshops\, roundtables\, and networking opportunities. The 2025 edition promises excellent visibility for research conducted in our region and for all stakeholders driving innovation in health.  \n\nProgram & registration: https://jobim2025.labri.fr\n\nRegistration open from May 15 to June 15\, 2025
URL:https://www.bricbordeaux.com/en/event/jobim-2025-open-days-in-biology-informatics-and-mathematics/
LOCATION:LaBRI
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/gclv2l9wiaaw6oe-scaled.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250901
DTEND;VALUE=DATE:20251001
DTSTAMP:20250814T125719Z
CREATED:20250814T124605Z
LAST-MODIFIED:20250814T125719Z
UID:49882-1756684800-1759276799@www.bricbordeaux.com
SUMMARY:Gynecological Cancer Awareness Month - Turquoise September
DESCRIPTION:As part of Septembre Turquoise\, Gynecological Cancer Awareness Month\, members of the 2.2 Oncology\, Gynecology\, and Proteostasis (OncoGyne) team led by Frederic Delom are participating in events organized by the Bergonié Institute. \n📅 From Monday\, September 1 to Tuesday\, September 30.\nProgram offered by the IMAGYN association\, a meeting and information space with the involvement of professionals from the Bergonié Institute. \n  \nProgram \n  \nMore information to come
URL:https://www.bricbordeaux.com/en/event/gynecological-cancer-awareness-month-turquoise-september/
LOCATION:Institut Bergonié\, 229 Cours de l'Argonne\, Bordeaux\, 33076\, France
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/08/septembre-turquoise-bergonie-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250909T110000
DTEND;TZID=Europe/Paris:20250909T120000
DTSTAMP:20250711T151927Z
CREATED:20250711T151927Z
LAST-MODIFIED:20250711T151927Z
UID:49733-1757415600-1757419200@www.bricbordeaux.com
SUMMARY:Invited seminar Gautier Follain - 09-09-2025
DESCRIPTION:The BRIC unit welcomes Gautier Follain for a seminar open to the scientific community. \n  \nGautier Follain\, PhD \nShared postdoctoral researcher between the laboratories of Pr. Johanna Ivaska (University of Turku) Dr. Guillaume Jacquemet (Åbo akademi)\, both located in Turku (Finland). \nDocent at the University of Turku\, Field of application: Biophysics of cancer. \n  \nDissecting the intravascular adhesion and extravasation of Pancreatic Ductal AdenoCarcinoma. \n📆 Tuesday\, September 9 11 a.m. \n📌 BBS conference room\, 2 rue Dr Hoffmann Martinot\, Bordeaux \n  \nAbstract. \nSolid tumor progression is a complex succession of events happening in different spaces and times in the body\, ultimately leading to the formation of life-threatening metastases. To colonize distant organs\, cancer cells are exploiting the circulatory networks as natural paths before stopping in small vessels and crossing the endothelial barrier. \nMy current research focuses on the steps of intravascular adhesion and extravasation (crossing of the vessel border) of pancreatic ductal adenocarcinoma (PDAC) cell lines. My main objectives are to decipher the mechanisms allowing the cells to break the endothelial barrier\, in an attempt to identify key factors and actors during the process. I work with microfluidic models to better reproduce the physiologic conditions of perfused vessels\, zebrafish embryos which are transparent and very rapidly develop a complex vascular system and murine models. All three are coupled with quantitative and high-resolution live imaging and to single cell characterization approaches (scRNAseq\,mass cytometry\,…). \nMy ongoing results support the idea that heterogeneity of cancer\, even among laboratory cell lines\, is driving different adhesion/extravasation routes that are dramatically understudied. My talk will give an overview of my postdoc projects. 1. FlowVision\, our deep-learning based image analysis framework\, allowing the dissection of the arrest to stabilisation of circulating PDAC and immune cells (Follain et al. BioRxiv 2024). 2. An unbiased enrichment-based screening for key actors of the intravascular adhesion step. 3. The discovery of a novel extravasation route used by PDAC cells. \n  \nBio. \nI did a PhD in life science in the lab. of Dr. Jacky Goetz (Strasbourg). I studied the role of blood flow forces on arrest\, adhesion and extravasation of circulating breast/mammary cells\, using multiple imaging modalities\, mostly applied to microfluidics and zebrafish embryos. I described endothelial remodeling around arrested tumor cells as an extravasation mechanism of cancer cells (Follain et al. Dev cell 2018). Our works demonstrated that not only size exclusion but also shear forces are biophysic parameters driving the metastatic spreading (Follain et al. NRC 2020).\nI moved to Turku as a shared postdoc between the well established Cell adhesion lab of J. Ivaska\, expert in integrin biology\, and the newly born lab of G. Jacquemet focusing on cellular protrusion and cell migration. I used similar models to study the metastatic cascade of pancreatic ductal adenocarcinoma. I added to my skill set deep-learning based image analysis (Follain et al. BioRxiv 2024)\, imaging techniques\, murine models and more. \nI am now looking for the next step of my career in France..!
URL:https://www.bricbordeaux.com/en/event/invited-seminar-gautier-follain-09-09-2025/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/07/gautier-follain-2025-09-09.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250918T080000
DTEND;TZID=Europe/Paris:20250918T120000
DTSTAMP:20250811T161757Z
CREATED:20250731T100014Z
LAST-MODIFIED:20250811T161757Z
UID:49856-1758182400-1758196800@www.bricbordeaux.com
SUMMARY:SBM Department Scientific Platforms Exhibition
DESCRIPTION:The SBM Department invites you to a special half-day event on Thursday\, September 18\, from 9 a.m. to 12 p.m.\, dedicated to scientific and technical platforms. This half-day event aims to raise awareness of the platforms’ activities and promote exchanges between doctoral students\, ITA/BIATSS\, scientists\, and any other interested staff. \nThe Platform exhibition will take place on the forecourt and/or in the lobby of the BBS (2 rue du Dr Hoffmann Martinot\, Bordeaux)\, depending on weather conditions. The programme includes : \n\nStands hosted by platform managers\nInteractive discussions and presentations\nA snack to share a convivial moment\n\nHow to participate? \n\nVisitors can simply come and explore the various stands at their own pace.\n\nFind all 18 platforms at this link. \n👉 Among them\, here are the platforms with a particular link to our BRIC unit: \n\nAquiDerm\nAquiDerm is the technology transfer structure of the team 05 – Translational Research In Oncodermatology and Orphan skin diseases (TRIO2)\, led by Hamid-Reza Rezvani and Marie Beylot-Barry\nOne of the platform’s scientific managers is Hamid-Reza Rezvani – with Julien Seneschal(ImmunoConcEpT)\, the co-managers are Jérôme Rambert and Muriel Cario\, and the scientific expert is Alain Taieb.\nIt is administratively attached to ADERA.\nCellOxia\nThe CellOxia hypoxia culture platform was created by Team 10 – Normal and Leukemic Hematopoietic Stem Cells\, led by Jean-Max Pasquet.\nThe scientific manager of the platform is Jean-Max Pasquet. The technical manager of the platform is Arnaud Villacreces.\nCrisp’edit\nThe CRISP’edit platform was created by Team 11 – Modeling Mechanisms of Transformation and Resistance in Leukemia\, led by Catherine Sawai.\nThe scientific manager of the core facility is Béatrice Turcq The technical manager of the platform is Valérie Prouzet-Mauleon.\nHistopath\nThe Histopathology core facility was created by Team 03 – Liver Cancers and Tumor Invasion\, led by Violaine Moreau and Frederic Saltel. Pierre Dubus (team 4)\, Brigitte Le bail (team 3)\, and Béatrice Turcq (team 11) are members of the Scientific Committee The technical manager of the core facility is Nathalie Dugot-Senant.\nOncoProt\nThe proteomic analysis core facility\, OncoProt\, was created by Team 03 – Liver Cancers and Tumor Invasion\, led by Violaine Moreau and Frederic Saltel\nThe scientific manager of the platform is Frederic Saltel\, and the technical manager is Anne-Aurélie Raymond.\nVect’UB\nThe vectorology platform\, Vect’UB\, was created by Team 08 – Genetic Biotherapies and Oncology (BioGO)\, led by Sandrine Dabernat and François Moreau-Gaudry. The scientific manager of the platform is François Moreau-Gaudry.\nThe technical manager of the platform is Véronique Guyonnet-Dupérat.\nVivOptic\nThe Vivoptic platform was created by the IMOTION team\, which joined Team 04 – Digestive cancers associated with Helicobacter infection\, cancer stem cells\, and therapeutic strategies\, led by Christine Varon. Christine Varon is a member of the scientific committee. The technical manager is Coralie Genevois.\nXenofish\nThe Xenofish platform was created by team 02 – Reprogramming of tumor activity and the associated microenvironment (Rytme)\, headed by A. Majid Khatib. The scientific manager of the platform is Géraldine Siegfried. The technical managers are Sandrine Fedou and Élodie Muzotte. The zootechnicians are Isabelle Auguste and Wendy Comandatore.\n\n 
URL:https://www.bricbordeaux.com/en/event/sbm-department-scientific-platforms-exhibition/
LOCATION:accueil Bâtiment BBS – Bordeaux Bioloie Santé\, 2 rue du Dr Hoffmann Martinot\, Bordeaux\, France
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/png:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/07/banniere-salonplateformes-37888b48d43df7f650a6adeac73e407e.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250922
DTEND;VALUE=DATE:20251011
DTSTAMP:20250918T160613Z
CREATED:20250522T104742Z
LAST-MODIFIED:20250918T160613Z
UID:49403-1758499200-1760140799@www.bricbordeaux.com
SUMMARY:Cancer Neuroscience School - Bordeaux - 09/22 to 10/02
DESCRIPTION:Antonio C. Pagano Zottola\, Junior Professor Team 1 – Tumor and Vascular Biology Laboratory of our unit is co-organizing a Cancer Neuroscience School in Bordeaux from September 22 to October 10\, 2025. with Anna Golebiewska\, Luxembourg Institute of Health et Varun Venkataramani\, German Cancer Research Center. \n  \nThis 3-week training course is aimed at scientists at Master 2 level and above. \n  \nProgram of seminars open to the scientific community \n  \nThe Bordeaux Neuroscience School is part of Bordeaux Neurocampus\, the neuroscience department of the University of Bordeaux. The school operates on the principle that training in neuroscience and oncology research involves hands-on experimentation in a real research laboratory. A number of renowned speakers in neuro-oncology will be taking part in the course.  \nWhat to expect? \n\nHands-on projects using cutting-edge technologies from neuroscience and oncology\,\nLectures by top scientists and a Brain Prize 2025 : Frank Winkler\,\nTechniques ranging from primary cultures and organoids to advanced imaging\,\nA collaborative\, interdisciplinary environment to boost your research skills.\n\n  \nFull details and registration \n  \nDeadline Extended: Apply by July 7th
URL:https://www.bricbordeaux.com/en/event/cancer-neuroscience-school-bordeaux-09-22-to-10-02/
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/05/cajal-school-cancer-neuroscience-2025-0910-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250923T133000
DTEND;TZID=Europe/Paris:20250923T170000
DTSTAMP:20250918T145053Z
CREATED:20250918T143354Z
LAST-MODIFIED:20250918T145053Z
UID:50017-1758634200-1758646800@www.bricbordeaux.com
SUMMARY:Thesis defense by Ruxue JIA
DESCRIPTION:Ruxue JIA will publicly defend her doctoral thesis in Cancer Biology\, supervised by Armelle MENARD\, Team 4: Digestive cancers associated with Helicobacter infection\, cancer stem cells\, and therapeutic strategies. \nTitle : Etude des voies de signalisation cellulaire modulées par les génotoxines bactériennes \nDefense scheduled for Tuesday\, September 23\, 2025\, at 1:30 p.m.\nAmphi 7\, Université de Bordeaux\, Campus Carreire\, 146 rue Leo Saignat 33000 Bordeaux \nNotice of defense with abstract available at this link (error in the notice)
URL:https://www.bricbordeaux.com/en/event/thesis-defense-by-ruxue-jia/
LOCATION:salles Nord et Sud – RDC Bâtimenet Bordeaux Biologie Santé (BBS)\, 2 rue du Dr Hoffmann Martinot\, Bordeaux\, France
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/09/soutenance-de-these-ruxue-jia-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20250924T140000
DTEND;TZID=Europe/Paris:20250924T170000
DTSTAMP:20250918T151552Z
CREATED:20250918T151552Z
LAST-MODIFIED:20250918T151552Z
UID:50028-1758722400-1758733200@www.bricbordeaux.com
SUMMARY:HDR thesis defense by Delphine Fessart
DESCRIPTION:Delphine Fessart\, team 2.2 Oncology & Gynecology Laboratory (OncoGyne)\, will defend her Habilitation à Diriger des Recherches (HDR) on Wednesday\, September 24\, at 2:00 p.m.\, in the Conference Room (R+7) of the Bergonié Institute. \nTitle : « Décrypter les mécanismes moléculaires conduisant au développement tumoral ».
URL:https://www.bricbordeaux.com/en/event/hdr-thesis-defense-by-delphine-fessart/
LOCATION:Institut Bergonié\, 229 Cours de l'Argonne\, Bordeaux\, 33076\, France
CATEGORIES:Meetings,Scientific seminars,Thesis defenses
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/09/soutenance-hdr-delphine-fessart.jpg
END:VEVENT
END:VCALENDAR